10 Results for "

NKTR

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "NKTR" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-A0118A
CAS No.: 1354744-91-4
Synonyms: NKTR-118 oxalate; AZ-13337019 oxalate
Target:  

Opioid Receptor

연구분야:  

Metabolic Disease

Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .
Cat. No.: HY-A0118
CAS No.: 854601-70-0
Synonyms: NKTR-118; AZ-13337019
Target:  

Opioid Receptor

연구분야:  

Neurological Disease Cancer

Naloxegol (NKTR-118; AZ-13337019) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol is applicable to research related to opioid-induced constipation .
Cat. No.: HY-RS09324
연구분야:  

Others

NKTR Human Pre-designed siRNA Set A contains three designed siRNAs for NKTR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS28781
연구분야:  

Others

Nktr Rat Pre-designed siRNA Set A contains three designed siRNAs for Nktr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-A0118S
Synonyms: NKTR-118-13C,d3; AZ-13337019-13C,d3
Naloxegol- 13C,d3 (NKTR-118- 13C,d3) is 13C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
Cat. No.: HY-A0118S1
Synonyms: NKTR-118-13C,d2; AZ-13337019-13C,d2
Naloxegol- 13C,d2 (NKTR-118- 13C,d2) is 13C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
Cat. No.: HY-109064
CAS No.: 1211231-76-3
Synonyms: Oxycodegol; NKTR-181
Target:  

Opioid Receptor

연구분야:  

Neurological Disease

Loxicodegol (Oxycodegol) is a first-in-class, long-acting, orally active, and selective mu-opioid agonist with structural properties that reduce its rate of entry across the blood-brain barrier compared with traditional mu-opioid agonists .
Cat. No.: HY-A0118AS
Naloxegol-d5 (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
Cat. No.: HY-RS22259
연구분야:  

Others

Nktr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nktr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-128861B
CAS No.: 1403357-80-1
Synonyms: Dimethylaminomicheliolide hydrochloride; DMAMCL hydrochloride
ACT001 (Dimethylaminomicheliolide; DMAMCL) hydrochloride is an orally active, blood-brain barrier-permeable anti-inflammatory and anti-tumor agent. ACT001 hydrochloride exerts microglia-mediated neuroanti-inflammatory effects by inhibiting the AKT/NF-κB/NLRP3 axis and suppressing apoptosis (apoptosis). ACT001 hydrochloride inhibits tumor proliferation by upregulating NKTR and inhibiting AKT. ACT001 hydrochloride alleviates metabolic-associated fatty liver disease by regulating gut microbiota and inhibiting ileal FXR. ACT001 hydrochloride inhibits pyroptosis (pyroptosis) and pro-inflammatory cytokine release by activating PPAR-γ and inhibiting NF-κB/NLRP3 .